The European Medicines Agency's controversial procedure on checking partial compliance of pediatric investigation plans prepared by drug companies under the EU Paediatric Regulation has been formally endorsed by the European Commission1. Whether the companies like it or not, the procedure is here to stay.
The commission's endorsement of the partial compliance check procedure comes in an updated guideline on the content and format of...




